US · ANIK · MEDICAL - DEVICES
Anika Therapeutics, Inc. (ANIK) intrinsic value and stock valuation
$13.23as of 2026-11-21 · Mkt cap 256.82M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Anika Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values ANIK with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ANIK’s statements →
Anika Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M |
| Operating income | -$-11.05M | -$-5.1M | $840K | $3.67M | $2.62M |
| Net income | -$-10.88M | -$-56.38M | -$-82.67M | -$-14.86M | $4.13M |
| EPSd | -$-758.72K | -$-3.83M | -$-5.64M | -$-1.02M | $282.3K |
| Operating cash flow | $11.2M | $5.4M | -$-1.79M | $4.41M | $8.4M |
| Capital expenditure | -$-6.83M | -$-7.73M | -$-5.43M | -$-7.49M | -$-5.14M |
| Free cash flow | $4.36M | -$-2.33M | -$-7.21M | -$-3.08M | $3.25M |
| Total assets | $190.3M | $202.7M | $270.6M | $349.1M | $347.5M |
| Total debt | $26.3M | $25.9M | $27.7M | $30.9M | $21M |
| Net debt | -$-31.23M | -$-29.7M | -$-41M | -$-55.44M | -$-73.43M |
| Total equity | $143.5M | $154M | $212.3M | $285.6M | $287.1M |
| Cash and short-term investments | $57.5M | $55.6M | $68.7M | $86.3M | $94.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M |
| Cost of revenue | $49M | $43.9M | $38.3M | $40.6M | $64.9M |
| Gross profit | $63.8M | $76M | $82.5M | $73.2M | $82.9M |
| Research and development expenses | $25.8M | $25.5M | $21.8M | $18.3M | $27.3M |
| Selling, general and administrative expenses | $49.1M | $55.6M | $59.9M | $51.2M | $74.1M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | -$-21.09M |
| Operating expenses | $74.9M | $81.1M | $81.7M | $69.6M | $80.3M |
| Cost and expenses | $123.9M | $125M | $120M | $110.2M | $145.2M |
| Interest income | $0.00 | — | $2.31M | $650K | — |
| Interest expense | $0.00 | — | $0.00 | $0.00 | — |
| Depreciation and amortization | $5.73M | $8.12M | $14.2M | $14.5M | $14.3M |
| Ebitda | -$-3.58M | $5.36M | $17.4M | $18.8M | -$-4.16M |
| Operating income | -$-11.05M | -$-5.1M | $840K | $3.67M | $2.62M |
| Total other income/expenses, net | $1.74M | $2.34M | $2.31M | $650K | -$-190K |
| Income before tax | -$-9.31M | -$-2.76M | $3.16M | $4.32M | $2.43M |
| Income tax expense | $670K | $6.06M | $6.59M | $2.12M | -$-1.71M |
| Net income | -$-10.88M | -$-56.38M | -$-82.67M | -$-14.86M | $4.13M |
| Weighted average shares outstanding | $14.3M | $14.7M | $14.7M | $14.6M | $14.4M |
| Weighted average diluted shares outstanding | $14.3M | $14.7M | $14.7M | $14.6M | $14.6M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $57.5M | $55.6M | $68.7M | $86.3M | $94.4M |
| Net receivables | $23.7M | $23.6M | $26.4M | $34.6M | $29.8M |
| Inventory | $18.8M | $23.8M | $24.4M | $39.8M | $36M |
| Total current assets | $103.4M | $113.7M | $163.3M | $169.6M | $168.5M |
| Property, plant and equipment, net | $66.3M | $64.7M | $65M | $79M | $68.6M |
| Goodwill and intangible assets | $9.7M | $9.62M | $10.2M | $81.9M | $90.2M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $86.9M | $89.1M | $107.3M | $179.6M | $179M |
| Total assets | $190.3M | $202.7M | $270.6M | $349.1M | $347.5M |
| Accounts payable | $6.04M | $5.62M | $6.19M | $9.07M | $7.63M |
| Short-term debt | $2.05M | $1.92M | $1.83M | $2.07M | $1.71M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $21.9M | $23.3M | $31.1M | $27.9M | $29.8M |
| Long-term debt | $24.2M | $24M | $25.9M | $28.8M | $19.2M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $24.9M | $25.5M | $27.3M | $35.7M | $30.7M |
| Capital lease obligations | $2.05M | $25.9M | $27.7M | $30.9M | $21M |
| Total liabilities | $46.8M | $48.8M | $58.4M | $63.6M | $60.5M |
| Common stock | $140K | $140K | $150K | $150K | $140K |
| Retained earnings | $60.8M | $71.7M | $128.1M | $210.7M | $225.6M |
| Accumulated other comprehensive income (loss) | -$-4.96M | -$-6.78M | -$-5.94M | -$-6.44M | -$-5.72M |
| Total equity | $143.5M | $154M | $212.3M | $285.6M | $287.1M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $26.3M | $25.9M | $27.7M | $30.9M | $21M |
| Net debt | -$-31.23M | -$-29.7M | -$-41M | -$-55.44M | -$-73.43M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-10.88M | -$-56.38M | -$-82.67M | -$-14.86M | $4.13M |
| Depreciation and amortization | $5.73M | $8.12M | $14.2M | $14.5M | $14.3M |
| Stock-based compensation | $10.1M | $13.1M | $15.2M | $14.3M | $11.1M |
| Change in working capital | -$-820K | -$-13.09M | -$-12.12M | -$-11.82M | -$-14.72M |
| Accounts receivable | $410K | $3.37M | -$-1.3M | -$-5.63M | -$-6.22M |
| Inventory | $30K | -$-9.42M | -$-11.4M | -$-6.87M | -$-6.62M |
| Accounts payable | $40K | -$-2.51M | -$-10K | $1.97M | -$-1.1M |
| Net cash provided by operating activities | $11.2M | $5.4M | -$-1.79M | $4.41M | $8.4M |
| Investments in property, plant and equipment | -$-6.83M | -$-7.73M | -$-5.43M | -$-7.49M | -$-5.14M |
| Acquisitions, net | $8.99M | $0.00 | $0.00 | $0.00 | -$-480K |
| Net cash used for investing activities | -$-400K | -$-8.33M | -$-5.43M | -$-7.49M | -$-3.12M |
| Common stock issued | $500K | $0.00 | $0.00 | $680K | $1.13M |
| Common stock repurchased | -$-9.48M | -$-10.91M | -$-5M | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-10.55M | -$-12.73M | -$-6.32M | -$-4.85M | -$-6.78M |
| Net change in cash | $320K | -$-15.71M | -$-13.46M | -$-8.06M | -$-1.43M |
| Cash at end of period | $57.5M | $57.2M | $72.9M | $86.3M | $94.4M |
| Operating cash flow | $11.2M | $5.4M | -$-1.79M | $4.41M | $8.4M |
| Capital expenditure | -$-6.83M | -$-7.73M | -$-5.43M | -$-7.49M | -$-5.14M |
| Free cash flow | $4.36M | -$-2.33M | -$-7.21M | -$-3.08M | $3.25M |
Line items
Line items
Line items
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
- CEO
- Stephen D. Griffin
- Employees
- 235
- Beta
- 0.19
Included in
Explore
Frequently asked questions
What is the intrinsic value of Anika Therapeutics, Inc. (ANIK)?
Anika Therapeutics, Inc. (ANIK) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ANIK undervalued?
ANIK trades at a price of $13.23 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.